Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

Long-term safety and effectiveness of etanercept in JIA: an 18-year experience from the BiKeR registry

Abstract Background At present, etanercept represents the most commonly prescribed biologic agent for juvenile idiopathic arthritis (JIA) treatment. Children and adolescents with JIA are often treated with etanercept over long periods, sometimes even into adulthood. The objectives of this analysis w...

Full description

Bibliographic Details
Main Authors: Giulia Armaroli, Ariane Klein, Gerd Ganser, Michael J. Ruehlmann, Frank Dressler, Anton Hospach, Kirsten Minden, Ralf Trauzeddel, Ivan Foeldvari, Jasmin Kuemmerle-Deschner, Frank Weller-Heinemann, Andreas Urban, Gerd Horneff
Format: Article
Language:English
Published: BMC 2020-10-01
Series:Arthritis Research & Therapy
Subjects:
Juvenile Idiopathic Arthritis
JIA treatment
Etanercept
TNF inhibitors
Biologics registry
Drug surveillance
Online Access:http://link.springer.com/article/10.1186/s13075-020-02326-5

Internet

http://link.springer.com/article/10.1186/s13075-020-02326-5

Similar Items